Prevention of hepatitis B virus reinfection after orthotopic liver transplantation

Hepatobiliary and Pancreatic Diseases International

Volumn 3, Issue 3, 2004, Pages 345-348

  Wang, Zheng Xin ^a   Ding, Guo Shan ^a   Fu, Hong ^a   Zhang, Jian Jun ^a   Chen, Xiao Song ^a   Guo, Wen Yuan ^a   Shi, Xiao Min ^a   Fu, Zhi Ren ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B; Hepatitis B immunoglobulin; Lamivudine; Liver transplantation; Prophylaxis; Reinfection

Indexed keywords

ADEFOVIR; GANCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LAMIVUDINE; PREDNISONE; VIRUS DNA;

ADULT; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORTHOTOPIC TRANSPLANTATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; REINFECTION;

ADENINE; ADULT; COMBINED MODALITY THERAPY; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; POSTOPERATIVE COMPLICATIONS; RECURRENCE; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 4444322744     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000;70:809-815.
2. Honaker MR, Shokouh-Amiri MH, Vera SR, Alloway RR, Grewal HP, Hardinger KL, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis 2002;4:137-143.
3. Lu SC, Yan LN, Li B, Wen TF, Zhao JC, Cheng NS, et al. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation. Hepatobiliary Pancreat Dis Int 2004;3:26-32.
4. Fontana RJ, Han HW, Wright T, Everson G, Baker A, Schiff ER, et al. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001;7:511-512.
5. Castells L, Vargas V, Rodriguez F, Allende H, Buti M, Sanchez-Avila JF, et al. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation. Liver Transpl 2002;8:892-900.
6. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001;7:113-117.
7. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am J Gastroenterol 2003;98:151-159.
8. Terrault NA. Treatment of recurrent hepatitis B infection in liver transplant recipients. Liver Transpl 2002;8:74-81.
9. Papatheodoridis GV, Sevastianous V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleos analogues era. Am J Transplant 2003;3:250-258.
10. Han SH, Martin P, Edelstein M, Hu R, Kunder G, Holt C, et al. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxix to prevent hepatitis B recurrence after liver transplantation. Liver Transpl 2003;9:182-187.
11. Faust D, Rabenau HF, Allwinn R, Caspary WF, Zeuzem S. Cost-effective and safe ambulatory long-term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation. Clin Transplant 2003;17:254-258.
12. Lo CM, Fan ST, Liu CL, Lai CL, Wong J. Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. Transplantation 2003;75:41-44.
13. Seehofer D, Rayes N, Steinmuller T, Muller AR, Jonas S, Settmacher U, et al. Combination prophylaxis with hepatitis B immunoglobulin and lamivudine after liver transplantation minimizes HBV recurrence rates unless evolution of pretransplant lamivudine resistance. Z Gastroenterol 2002;40:795-799.
14. Engler S, Sauer P, Klar E, Stremmel W, Kallinowski B. Prophylaxis of hepatitis B recurrence after liver transplantation with lamivudine and hepatitis B immunoglobulin. Transplant Proc 2002;34:2285-2287.
15. Marzan A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001;34:943-945.
16. Steven-Huy BH, Joshua O, Curtis H, Kevin K, gregg K, Pauline C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplantation 2000;6:741-748.
17. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003;3:999-1002.
18. Lu SC, Yan LN, Li B, Ma YK, Liu C, Wen TF, et al. Dynamic alteration of HBV markers on active HBV replicative recipients after liver transplantation: a preliminary report. Hepatobiliary Pancreat Dis Int 2003;2:196-201.
19. Zheng SS, Wu J, Liang TB, Wang WL, Huang DS, Xu X. Prophylaxis and treatment of hepatitis B virus reinfection following liver transplantation. Hepatobiliary Pancreat Dis Int 2002;1:327-329.
20. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999;29:1581-1586.
21. Reyes N, Seehofer D, Hopf U, Neuhaus R, Naumann U, Bechstein WO, et al. Comparison of famciclovir and lamivudine in the long-term treatment of hepatitis B infection after liver transplantation. Transplantation 2001;71:96-101.
22. Ben-Ari Z, Mor E, Tur-Kaspa R. Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J Intern Med 2003;253:544-552.
23. Walsh KM, Woodall T, Lamy P, Wight DG, Bloor S, Alexander GJ. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus. Gut 2001;49:40.
24. Naoumov NV, Lopes AR, Burra P, Caccamo L, Iemmolo RM, de Man RA, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long term prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-894.
25. Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, et al. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg 2002; 235: 611-619.
26. Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000;6:741-748.
27. Saab S, Kim M, Wright TL, Han SH, Martin P, Busuttil RW. Successful orthotopic liver transplantation for lamivudine-associated YMDD mutant hepatitis B virus. Gastroenterology 2000;119:1382-1384.
28. Buti M, Mas A, Prieto M, Casafont F, Gonzalez A, Miras M, et al. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003;38:811-817.
29. Rosenau J, Bahr MJ, Tillmann HL, Trautwein C, Klempnauer J, Manns MP, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001;34:895-902.
30. Lo CM, Fung JT, Lau GK, Liu CL, Cheung ST, Lai CL, et al. Development of antibody to hepatitis surface antigen after liver transplantation for chronic hepatitis B. Hepatology 2003; 37:36-43.